Answers are grounded in this paper and cite their sources.
The interleukin (IL)-1-family receptor antagonist IL-38 has emerged as a negative regulator of auto-inflammation. Given the intricate interplay between antitumor immunity and auto-inflammation, we hypothesized that blocking IL-38 may enhance tumor immune control.
No takes yet. Share an insight, caveat, or question.
Silva et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: